Evidence map›Paper›PMID 28789390›Full record

ArticleOncology letters2017

Prognostic significance of sarcopenia in patients with hepatocellular carcinoma undergoing sorafenib therapy.

Hiroki Nishikawa, Norihiro Nishijima, Hirayuki Enomoto, Azusa Sakamoto, Akihiro Nasu, Hideyuki Komekado, Takashi Nishimura, Ryuichi Kita, Toru Kimura, Hiroko Iijima and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. The egyptian clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
    Guideline
  8. Trial
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hiroki NishikawaDivision of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan.
Norihiro NishijimaDepartment of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka 543-8555, Japan.
Hirayuki EnomotoDivision of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan.
Azusa SakamotoDepartment of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka 543-8555, Japan.
Akihiro NasuDepartment of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka 543-8555, Japan.
Hideyuki KomekadoDepartment of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka 543-8555, Japan.
Takashi NishimuraDivision of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan.
Ryuichi KitaDepartment of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka 543-8555, Japan.
Toru KimuraDepartment of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka 543-8555, Japan.
Hiroko IijimaDivision of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan.
Shuhei NishiguchiDivision of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan.
Yukio OsakiDepartment of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka 543-8555, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present study aimed to examine the impact of sarcopenia, defined as low muscle mass on computed tomography (CT), prior to sorafenib therapy on the clinical outcomes of patients with hepatocellular carcinoma (HCC) receiving sorafenib therapy. In total, 232 patients with unresectable HCC (median age, 72 years) were analyzed, and the extent of sarcopenia was assessed using CT. Cross-sectional areas (cm

Indexed as

hepatocellular carcinomaoverall survivalprognostic impactprogression-free survivalsarcopeniasorafenib

Identifiers

PMID28789390
PMCPMC5529937

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.